FIELD: medicine.
SUBSTANCE: invention refers to cosmetic and pharmaceutical industry and represents a method for improving the transdermal permeability of therapeutic or cosmetic topical preparations involving the dermal administration of 1.0 to 300.0 vol. % of liquid xenon as a part of an acceptable neutral carrier or a therapeutic or cosmetic preparation.
EFFECT: invention provides the higher therapeutic or cosmetic effectiveness ensured by improving the transdermal transport of bioactive compounds.
8 cl, 13 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIOXIDANT FOR COSMETIC AGENTS AND COSMETIC AGENTS | 2007 |
|
RU2362540C1 |
| METHOD OF INCREASING DEGREE OF PENETRATION AND EFFECTIVENESS OF TOPICAL AGENTS WITH STABLE LONG-TERM CONTENT OF INERT GAS | 2023 |
|
RU2814767C1 |
| XENON APPLICATION FOR CORRECTION OF ORGANISM LESIONS ASSOCIATED WITH ANTIOXIDANT STATUS DISORDER | 2006 |
|
RU2346695C2 |
| APPLICATION OF XENON FOR RETENTION OF ANTIOXIDANT PROPERTIES OF SEA-BUCKTHORN OIL | 2006 |
|
RU2325188C1 |
| METHOD FOR IMPROVING THE CONDITION OF THE SKIN AND SUBCUTANEOUS TISSUES | 2022 |
|
RU2789964C1 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS | 2020 |
|
RU2742879C1 |
| LOCAL AND EXTERNAL SYGETHIN-BASED PHARMACEUTICAL COMPOSITION APPLIED IN MENOPAUSAL DISORDERS | 2007 |
|
RU2360670C1 |
| STEPHAGLABRIN-BASED PHARMACEUTICAL COMPOSITION OF LOCAL AND EXTERNAL APPLICATION FOR TREATMENT OF TRAUMATIC AND POST-OPERATION INJURY OF PERIPHERAL NERVOUS SYSTEM | 2007 |
|
RU2371172C2 |
| METHOD OF INTRODUCING XENON INTO THE HUMAN BODY DURING XENON THERAPY | 2018 |
|
RU2706424C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING LYSINE, PROLINE AND TRITERPENIC ACID DERIVATIVES FOR TREATING AND PREVENTING VIRAL INFECTIONS CAUSED BY RNA- AND DNA-CONTAINING VIRUSES, SUCH AS: INFLUENZA, HERPES, HERPES ZOSTER, HUMAN PAPILLOMA, ADENOVIRUSES, AS WELL AS BACTERIAL INFECTIONS CAUSED BY GRAM-POSITIVE AND GRAM-NEGATIVE MICROORGANISMS | 2013 |
|
RU2535052C1 |
